Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis

INTRODUCTION: Despite the well-documented benefits of prophylaxis, treatment burden is still a barrier to adherence in patients with haemophilia. An extended half-life fusion protein linking recombinant FIX (rFIX) with human albumin (rIX-FP) has been developed for the treatment of patients with haem...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Adv Ther
Autori principali: Hermans, Cedric, Marino, Renato, Lambert, Catherine, Mangles, Sarah, Sommerer, Patrick, Rives, Vincent, Maro, Geraldine, Malcangi, Giuseppe
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Healthcare 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467451/
https://ncbi.nlm.nih.gov/pubmed/32333327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01300-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi